Science AI Journal
Biochemistry, Genetics and Molecular Biology · Research topic

Open research questions in Cancer Research and Treatments

137 gap statements mined from Cancer Research and Treatments papers in our 4.5M-paper local library, which holds 824 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Cancer Research and Treatments? See the ranked Biology journals.

What the literature leaves open

  • First, SN-38 production was inferred indirectly through functional cytotoxicity rather than direct metabolite quantification, and, therefore, the precise intratumoral pharmacokinetics remain to be determined. Several limitations of this study should also be acknowledged.

    Carboxylesterase 2-Engineered Stem Cell Therapy Shows Superior Efficacy over Cytosine Deaminase in Castration-Resistant Prostate Cancer · 2026 · DOI

  • This emerging field holds considerable promise but is also accompanied by significant challenges. Rational utilization of intratumoral microbiota may enable the development of new frameworks for early cancer diagnosis, multimodal treatment strategies, and assessment of prognosis and therapeutic response, which represent central directions for future research.

    Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications · 2026 · DOI

  • Current bacterial therapies have limitations, including safety concerns and the need for repeat dosing. There is a need for a practicable method for bacterial immunotherapies. There is a need for a sustained delivery method for immunomodulatory molecules.

    Tumor-targeted aptamer-conjugated engineered bacteria for CXCL9 cytokine delivery in non-small cell lung cancer immunotherapy · 2026 · DOI

  • While the bacterial microbiome is a recognized modulator of the tumor microenvironment (TME), the non-bacterial oncobiome, comprising the mycobiome (fungi) and virome (viruses), represents a critical but under-explored frontier in cellular adaptability.

    The non-bacterial oncobiome: the role of the mycobiome and virome in tumor plasticity · 2026 · DOI

  • Results have remained inconsistent, possibly due to differences in metabolic adaptations across molecular breast cancer subtypes. Gene expression does not necessarily correlate directly to protein expression.

    L-arginine metabolism in breast cancer: mechanisms and therapeutic targets · 2026 · DOI

  • Current evidence remains limited by small studies, heterogeneous endpoints, and insufficient long-term follow-up. The evolution and timeline of major discoveries for living cancer therapeutics are not fully understood.

    Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics · 2026 · DOI

  • The lack of understanding of the mechanisms that convert poorly inflamed tumors into lesions capable of supporting productive antitumor immunity. The need to identify novel approaches to sensitize microsatellite-stable colorectal cancer to immune checkpoint blockade immunotherapy.

    Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis · 2026 · DOI

  • The prognosis and quality of life for patients with advanced disease remain suboptimal. Current treatment strategies have limitations, and new approaches are needed.

    Phytochemicals remodel antitumor immunity via the “microbiota–metabolite–receptor” axis: focus on colorectal cancer and immunotherapy · 2026 · DOI

  • The current treatment strategies for CRC have limitations, and new approaches are needed. The role of phytochemicals in remodeling antitumor immunity via the microbiota-metabolite-receptor axis is not fully understood.

    Phytochemicals remodel antitumor immunity via the “microbiota–metabolite–receptor” axis: focus on colorectal cancer and immunotherapy · 2026 · DOI

  • The need for a better understanding of the effects of microbiome-derived metabolites on host physiology. The need for standardized methods for analyzing and interpreting microbiome data. The need for further research on the potential therapeutic applications of microbiome-derived metabolites.

    Microbiome-derived bioactive molecules regulate host signaling and therapeutic responses in cancer and metabolic diseases · 2026 · DOI

  • Mechanistic studies should connect tumor-intrinsic signaling to immune, stromal, metabolic, and stress-response programs. Biomarker development should progress from single-gene markers to multidimensional signatures. Emerging approaches to TME remodeling and precision treatment should be further developed.

    Editorial: Progress in molecular mechanisms and targeted therapies for solid tumor microenvironments · 2026 · DOI

  • The interactions between tumor-intrinsic alterations and stromal, immune, metabolic, and stress-response programs are not well understood. Prior work has focused on individual signaling pathways, but a more holistic approach is needed.

    Editorial: Progress in molecular mechanisms and targeted therapies for solid tumor microenvironments · 2026 · DOI

  • The need to develop biological strategies to enhance nanomedicine performance. The challenge of delivering nanomedicine to the target site and achieving optimal therapeutic efficacy.

    Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer · 2026 · DOI

  • Our work demonstrates that activation of APCCDH1 by our C43-4 peptide is necessary to reverse the aggressive behavior of drug resistant breast cancer cells and supports further study into using APCCDH1 as a valuable therapeutic target for improving patient outcomes.

    Restoration of chemosensitivity to drug resistant breast cancer cells through peptide activation of the anaphase promoting complex · 2026 · DOI

  • The limited drug-like properties of gut microbial metabolites. The need to increase the oral absorption and half-life of 3,4-dihydroxybenzoic acid. The challenge of inducing a long-term protective antitumour response.

    Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy · 2026 · DOI

  • The limited drug-like properties of gut microbial metabolites. The lack of understanding of the mechanisms of gut microbial metabolites in regulating systemic immunity. The need for a novel approach to harness the potency of gut microbial metabolites for cancer immunotherapy.

    Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy · 2026 · DOI

  • It highlights the need for further research on the double-edged sword effect of Enterococcus on malignant tumor therapy.

    Enterococcus and cancer: from mechanistic insights to clinical translation · 2026 · DOI

  • While syngeneic models (such as EO771) are widely used to understand therapeutic response due to their immunocompetent context, the extent to which these systems recapitulate the spatial tumor architecture and ECM organization observed in patient TNBC remains poorly defined.

    Characterizing spatial tumor architecture and ECM recapitulation using an EO771 syngeneic TNBC model. · 2026 · DOI

  • Future investigations should adopt a multi-omics approach, including targeted metabolomic and proteomic profiling of quercetin-adapted L.

    Long-term exposure of Lactobacillus rhamnosus to quercetin enhances its anti-angiogenic and anti-colorectal cancer efficacy · 2026 · DOI

  • The evidence is not yet strong enough to support the sweeping claim that bacteria are stable and biologically decisive constituents across cancers in general. The study acknowledges that the data remain primarily associative and should be described at the threshold they actually reach.

    Intratumoral bacteria in cancer: from detection to biological relevance · 2026 · DOI

  • Investigation of the mechanisms underlying the associations between microbial and metabolic changes and treatment response and toxicity - Development of personalized medicine approaches based on individual microbiome and metabolome…

    Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity · 2026 · DOI

  • Limited understanding of the dynamics of the fecal microbiome and metabolome during iTNT - Need for non-invasive biomarkers and functional clues for optimizing…

    Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity · 2026 · DOI

  • Investigation of the mechanisms by which the microbiome regulates MHC-II expression in colon cancer cells. Development of novel therapies that target the microbiome to enhance anti-tumor immunity. Exploration of the applicability of the study's approach to other types of cancer.

    Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis · 2026 · DOI

  • Investigating the therapeutic efficacy in other cancer models, - Exploring the potential of microbial levan in combination with other nanomedicines, - Conducting clinical trials to translate the findings…

    Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer · 2026 · DOI

  • The study was restricted to a single CRC cell line (SW-480) under in vitro conditions, which limits the extrapolation of findings across the molecular and clinical heterogeneity of colorectal cancer - The specific bioactive constituents and underlying molecular pathways responsible for the enhanced activity of que-CFS remain…

    Long-term exposure of Lactobacillus rhamnosus to quercetin enhances its anti-angiogenic and anti-colorectal cancer efficacy · 2026 · DOI

Most-cited papers in Cancer Research and Treatments

Most recent work

Find a gap in your own Cancer Research and Treatments sub-topic

This page shows what the Cancer Research and Treatments literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 4.5M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Biochemistry, Genetics and Molecular Biology

Gut microbiota and health
2,514 open questions
Single-cell and spatial transcriptomics
864 open questions
Extracellular vesicles in disease
854 open questions
RNA modifications and cancer
830 open questions
Antibiotic Resistance in Bacteria
732 open questions
Genetic Associations and Epidemiology
627 open questions
Mitochondrial Function and Pathology
609 open questions
Epigenetics and DNA Methylation
542 open questions
Open questions raised by papers listed on this page include: (1) SN-38 production was inferred indirectly through functional cytotoxicity rather than direct metabolite quantification, and, therefore, the precise intratumoral pharmacokinetics remain to be determined (“Carboxylesterase 2-Engineered Stem Cell Therapy Shows Superior Efficacy over…”, 2026); (2) There is a need for a practicable method for bacterial immunotherapies (“Tumor-targeted aptamer-conjugated engineered bacteria for CXCL9 cytokine…”, 2026); (3) Current evidence remains limited by small studies, heterogeneous endpoints, and insufficient long-term follow-up (“Oncobiotics in urinary bladder cancer. A narrative review of living cancer…”, 2026); (4) The lack of understanding of the mechanisms that convert poorly inflamed tumors into lesions capable of supporting productive antitumor immunity (“Microbial induction of MHC-II expression in colon cancer cells overcomes…”, 2026); (5) Current treatment strategies have limitations, and new approaches are needed (“Phytochemicals remodel antitumor immunity via the…”, 2026). 137 gap statements have been mined from Cancer Research and Treatments papers in our 4.5M-paper local library, which holds 824 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.